2015 Q4 Form 10-Q Financial Statement
#000114420415063720 Filed on November 09, 2015
Income Statement
Concept | 2015 Q4 | 2015 Q3 | 2014 Q4 |
---|---|---|---|
Revenue | $338.0K | $25.00K | $0.00 |
YoY Change | |||
Cost Of Revenue | $0.00 | ||
YoY Change | |||
Gross Profit | $25.00K | ||
YoY Change | |||
Gross Profit Margin | 100.0% | ||
Selling, General & Admin | $7.210M | $8.079M | $3.200M |
YoY Change | 125.31% | 194.85% | 7.74% |
% of Gross Profit | 32316.0% | ||
Research & Development | $5.760M | $9.073M | $1.770M |
YoY Change | 225.42% | 463.89% | -72.98% |
% of Gross Profit | 36292.0% | ||
Depreciation & Amortization | $10.00K | $6.000K | $0.00 |
YoY Change | 0.0% | -100.0% | |
% of Gross Profit | 24.0% | ||
Operating Expenses | $12.96M | $18.10M | $4.960M |
YoY Change | 161.29% | 316.41% | -47.9% |
Operating Profit | -$12.96M | -$18.10M | -$4.961M |
YoY Change | 161.32% | 316.41% | -47.91% |
Interest Expense | -$2.450M | $350.0K | $1.250M |
YoY Change | -296.0% | 189.26% | -562.96% |
% of Operating Profit | |||
Other Income/Expense, Net | -$1.783M | ||
YoY Change | 624.8% | ||
Pretax Income | -$15.08M | -$19.86M | -$3.710M |
YoY Change | 306.47% | 332.68% | -62.14% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$12.04M | -$18.16M | -$3.713M |
YoY Change | 224.16% | 295.49% | -62.1% |
Net Earnings / Revenue | -3560.95% | -72644.0% | |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$305.0K | -$460.8K | -$99.30K |
COMMON SHARES | |||
Basic Shares Outstanding | 47.13M shares | 46.83M shares | 44.31M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2015 Q4 | 2015 Q3 | 2014 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $98.20M | $69.61M | $73.92M |
YoY Change | 32.84% | -2.78% | -25.71% |
Cash & Equivalents | $98.18M | $25.56M | $49.76M |
Short-Term Investments | $44.05M | $24.16M | |
Other Short-Term Assets | $1.600M | $1.100M | $700.0K |
YoY Change | 128.57% | 175.0% | 40.0% |
Inventory | $0.00 | ||
Prepaid Expenses | |||
Receivables | $0.00 | ||
Other Receivables | $200.0K | ||
Total Short-Term Assets | $99.94M | $66.60M | $70.46M |
YoY Change | 41.83% | -7.59% | -29.56% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $309.0K | $100.0K | $52.00K |
YoY Change | 494.23% | 72.41% | -88.37% |
Goodwill | $0.00 | ||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | $250.0K | $250.0K | $250.0K |
YoY Change | 0.0% | -16.67% | |
Other Assets | $43.00K | $14.80M | $64.00K |
YoY Change | -32.81% | 8076.8% | -38.46% |
Total Long-Term Assets | $18.67M | $20.26M | $18.86M |
YoY Change | -1.0% | 27.17% | 3323.23% |
TOTAL ASSETS | |||
Total Short-Term Assets | $99.94M | $66.60M | $70.46M |
Total Long-Term Assets | $18.67M | $20.26M | $18.86M |
Total Assets | $118.6M | $86.86M | $89.33M |
YoY Change | 32.78% | -1.3% | -11.19% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.868M | $1.287M | $366.0K |
YoY Change | 410.38% | 286.49% | -21.79% |
Accrued Expenses | $8.570M | $7.137M | $3.683M |
YoY Change | 132.69% | 123.03% | -16.86% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $10.58M | $8.450M | $4.077M |
YoY Change | 159.48% | 137.56% | -63.63% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $23.20M | $23.30M | $14.00M |
YoY Change | 65.71% | 66.43% | 100.0% |
Other Long-Term Liabilities | $584.0K | $202.0K | $722.0K |
YoY Change | -19.11% | -74.53% | -32.96% |
Total Long-Term Liabilities | $584.0K | $202.0K | $722.0K |
YoY Change | -19.11% | -82.9% | -32.96% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $10.58M | $8.450M | $4.077M |
Total Long-Term Liabilities | $584.0K | $202.0K | $722.0K |
Total Liabilities | $34.34M | $31.94M | $18.80M |
YoY Change | 82.62% | 70.39% | -2.6% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$190.2M | -$178.1M | -$141.7M |
YoY Change | 34.17% | 29.06% | 16.8% |
Common Stock | $47.00K | $47.00K | $46.00K |
YoY Change | 2.17% | 6.82% | 15.0% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $56.85M | $53.60M | $70.52M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $118.6M | $86.86M | $89.33M |
YoY Change | 32.78% | -1.3% | -11.19% |
Cashflow Statement
Concept | 2015 Q4 | 2015 Q3 | 2014 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$12.04M | -$18.16M | -$3.713M |
YoY Change | 224.16% | 295.49% | -62.1% |
Depreciation, Depletion And Amortization | $10.00K | $6.000K | $0.00 |
YoY Change | 0.0% | -100.0% | |
Cash From Operating Activities | $2.860M | -$15.17M | -$3.520M |
YoY Change | -181.25% | 457.72% | -50.7% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$190.0K | -$40.00K | $0.00 |
YoY Change | -100.0% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $29.49M | -$11.33M | -$22.67M |
YoY Change | -230.08% | 22560.0% | 15013.33% |
Cash From Investing Activities | $29.30M | -$11.37M | -$22.67M |
YoY Change | -229.25% | 22640.0% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 40.46M | 11.07M | 4.370M |
YoY Change | 825.86% | -868.75% | 1020.51% |
NET CHANGE | |||
Cash From Operating Activities | 2.860M | -15.17M | -3.520M |
Cash From Investing Activities | 29.30M | -11.37M | -22.67M |
Cash From Financing Activities | 40.46M | 11.07M | 4.370M |
Net Change In Cash | 72.62M | -15.47M | -21.82M |
YoY Change | -432.81% | 267.46% | 223.26% |
FREE CASH FLOW | |||
Cash From Operating Activities | $2.860M | -$15.17M | -$3.520M |
Capital Expenditures | -$190.0K | -$40.00K | $0.00 |
Free Cash Flow | $3.050M | -$15.13M | -$3.520M |
YoY Change | -186.65% | 456.25% | -51.71% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2015Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1287000 | USD |
CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
366000 | USD |
CY2015Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
26000 | USD |
CY2014Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
28000 | USD |
CY2015Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7137000 | USD |
CY2014Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3683000 | USD |
CY2015Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8450000 | USD |
CY2015Q3 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
23291000 | USD |
CY2014Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
14003000 | USD |
CY2014Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
722000 | USD |
CY2014Q4 | us-gaap |
Liabilities
Liabilities
|
18802000 | USD |
CY2015Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
39951000 | USD |
CY2014Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
20002000 | USD |
CY2015Q3 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
14586000 | USD |
CY2014Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
14586000 | USD |
CY2015Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1250000 | USD |
CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
0 | USD |
CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
70523000 | USD |
CY2014Q4 | us-gaap |
Minority Interest
MinorityInterest
|
0 | USD |
CY2014Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
70523000 | USD |
CY2014Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1609000 | USD |
CY2015Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9073000 | USD |
CY2014Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2737000 | USD |
CY2015Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7129000 | USD |
CY2014Q3 | fbio |
Accretion And Interest Expenses
AccretionAndInterestExpenses
|
121000 | USD |
CY2015Q3 | fbio |
Accretion And Interest Expenses
AccretionAndInterestExpenses
|
350000 | USD |
CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4592000 | USD |
CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18161000 | USD |
CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.13 | |
CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.46 | |
CY2014Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36024810 | shares |
CY2015Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39412056 | shares |
CY2014Q3 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-293000 | USD |
CY2015Q3 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-1472000 | USD |
CY2015Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
39000 | USD |
CY2014Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
168000 | USD |
CY2015Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
18097000 | USD |
CY2014Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
4346000 | USD |
CY2015Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1783000 | USD |
CY2014Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-246000 | USD |
CY2015Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-19855000 | USD |
CY2014Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-4592000 | USD |
CY2015Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-1694000 | USD |
CY2015Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
202000 | USD |
CY2015Q3 | us-gaap |
Liabilities
Liabilities
|
31943000 | USD |
CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4077000 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
195000 | USD | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
517000 | USD | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7218000 | USD | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
14376000 | USD | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.46 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.93 | ||
CY2015Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
47000 | USD |
CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
46000 | USD |
CY2015Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
231684000 | USD |
CY2014Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
212205000 | USD |
CY2015Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-178120000 | USD |
CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-141728000 | USD |
CY2015Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
86864000 | USD |
CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
89325000 | USD |
CY2014Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
0 | USD |
CY2015Q3 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
1895000 | USD |
CY2014Q3 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
0 | USD |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8473000 | USD | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13172000 | USD | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15691000 | USD | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-37905000 | USD | |
fbio |
Accretion And Interest Expenses
AccretionAndInterestExpenses
|
1206000 | USD | |
fbio |
Accretion And Interest Expenses
AccretionAndInterestExpenses
|
1033000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-16673000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-36392000 | USD | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
35977355 | shares | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39038522 | shares | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-903000 | USD | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-982000 | USD | |
us-gaap |
Profit Loss
ProfitLoss
|
-38808000 | USD | |
us-gaap |
Profit Loss
ProfitLoss
|
-16673000 | USD | |
us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-2416000 | USD | |
us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
0 | USD | |
us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
10882000 | USD | |
us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
0 | USD | |
CY2015Q3 | us-gaap |
Revenues
Revenues
|
25000 | USD |
CY2014Q3 | us-gaap |
Revenues
Revenues
|
0 | USD |
us-gaap |
Revenues
Revenues
|
525000 | USD | |
us-gaap |
Revenues
Revenues
|
0 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11896000 | USD | |
us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
167000 | USD | |
us-gaap |
Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
|
11000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
394000 | USD | |
us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
-2000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
4375000 | USD | |
us-gaap |
Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
|
0 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-23239000 | USD | |
us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
1250000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-21412000 | USD | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | USD | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
216000 | USD | |
us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD | |
us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
0 | USD | |
us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
10000000 | USD | |
us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
0 | USD | |
us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
130000 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
17000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
20455000 | USD | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-24196000 | USD | |
CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
99521000 | USD |
us-gaap |
Interest Paid
InterestPaid
|
80000 | USD | |
us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
1000 | USD | |
us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
0 | USD | |
us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
855000 | USD | |
us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
17000 | USD | |
us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
143000 | USD | |
us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
0 | USD | |
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
0 | USD | |
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
345000 | USD | |
us-gaap |
Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
|
0 | USD | |
us-gaap |
Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
|
250000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
94000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD | |
fbio |
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan
|
26000 | USD | |
fbio |
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan
|
0 | USD | |
CY2015Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
14600000 | USD |
CY2015Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
8501000 | USD |
CY2014Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
1484000 | USD |
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
11896000 | USD | |
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
4082000 | USD | |
CY2014Q4 | us-gaap |
Trading Securities
TradingSecurities
|
20002000 | USD |
CY2014Q4 | us-gaap |
Equity Method Investments Fair Value Disclosure
EquityMethodInvestmentsFairValueDisclosure
|
4160000 | USD |
CY2014Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
24162000 | USD |
CY2015Q3 | us-gaap |
Trading Securities
TradingSecurities
|
39951000 | USD |
CY2015Q3 | us-gaap |
Equity Method Investments Fair Value Disclosure
EquityMethodInvestmentsFairValueDisclosure
|
4095000 | USD |
CY2015Q3 | us-gaap |
Marketable Securities
MarketableSecurities
|
44046000 | USD |
CY2015Q3 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
250000 | USD |
us-gaap |
Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
|
0.254 | pure | |
CY2015Q3 | us-gaap |
Share Price
SharePrice
|
9.49 | |
us-gaap |
Investments In And Advances To Affiliates At Fair Value Period Increase Decrease
InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease
|
1400000 | USD | |
CY2015Q3 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
3800000 | USD |
CY2015Q3 | fbio |
Working Capital
WorkingCapital
|
500000 | USD |
CY2015Q3 | fbio |
Working Capital Committed
WorkingCapitalCommitted
|
100000 | USD |
CY2015Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
|
3200000 | USD |
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y11M12D | ||
CY2015Q3 | fbio |
Employee Stock Purchase Plan Number Of Shares Purchased By Employees
EmployeeStockPurchasePlanNumberOfSharesPurchasedByEmployees
|
77875 | shares |
CY2015Q3 | fbio |
Employee Stock Purchase Plan Number Of Shares Available For Future Sale
EmployeeStockPurchasePlanNumberOfSharesAvailableForFutureSale
|
122125 | shares |
CY2015Q3 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
12600 | USD |
CY2014Q3 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
4200 | USD |
fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
27500 | USD | |
fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
19900 | USD | |
CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2164365 | shares |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares | |
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
100000 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
285000 | shares | |
CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1779365 | shares |
CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
1632698 | shares |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | ||
CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.69 | |
CY2015Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
302000 | USD |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.15 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
7.57 | ||
CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.37 | |
CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
4.40 | |
CY2015Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
45000 | USD |
CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | USD |
CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
0 | USD |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P6Y5M12D | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y6M25D | ||
CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y4M17D | |
CY2015Q3 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
961000 | USD |
CY2014Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
598000 | USD |
CY2014Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
837000 | USD |
CY2015Q3 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
589000 | USD |
CY2014Q4 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
832000 | USD |
CY2015Q3 | fbio |
Other Short Term Liabilities Related To Manufacturing Rights
OtherShortTermLiabilitiesRelatedToManufacturingRights
|
1500000 | USD |
CY2014Q4 | fbio |
Other Short Term Liabilities Related To Manufacturing Rights
OtherShortTermLiabilitiesRelatedToManufacturingRights
|
1000000 | USD |
CY2015Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
291000 | USD |
CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
213000 | USD |
CY2015Q3 | fbio |
Other Long Term Liabilities Related To Manufacturing Rights
OtherLongTermLiabilitiesRelatedToManufacturingRights
|
0 | USD |
CY2014Q4 | fbio |
Other Long Term Liabilities Related To Manufacturing Rights
OtherLongTermLiabilitiesRelatedToManufacturingRights
|
334000 | USD |
CY2015Q3 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
120000 | USD |
CY2014Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
120000 | USD |
CY2015Q3 | fbio |
Lease Abandonment Non Current
LeaseAbandonmentNonCurrent
|
82000 | USD |
CY2014Q4 | fbio |
Lease Abandonment Non Current
LeaseAbandonmentNonCurrent
|
268000 | USD |
CY2015Q3 | us-gaap |
Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
|
6000 | USD |
CY2014Q4 | us-gaap |
Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
|
38000 | USD |
CY2015Q3 | fbio |
Lease Impairment Current
LeaseImpairmentCurrent
|
165000 | USD |
CY2014Q4 | fbio |
Lease Impairment Current
LeaseImpairmentCurrent
|
165000 | USD |
CY2014Q4 | us-gaap |
Capital Leases Future Minimum Payments Receivable Current
CapitalLeasesFutureMinimumPaymentsReceivableCurrent
|
500000 | USD |
us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
167000 | USD | |
us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
114000 | USD | |
CY2015Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
188000 | USD |
CY2014Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
94000 | USD |
CY2015Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
59000 | USD |
CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
42000 | USD |
CY2015Q3 | us-gaap |
Depreciation
Depreciation
|
5700 | USD |
CY2014Q3 | us-gaap |
Depreciation
Depreciation
|
6000 | USD |
us-gaap |
Depreciation
Depreciation
|
17100 | USD | |
us-gaap |
Depreciation
Depreciation
|
17000 | USD | |
CY2015Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
24009000 | USD |
CY2014Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
14009000 | USD |
CY2015Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
718000 | USD |
CY2014Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
6000 | USD |
CY2015Q3 | us-gaap |
Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
|
0.113 | pure |
CY2015Q3 | us-gaap |
Interest Expense
InterestExpense
|
350000 | USD |
CY2014Q3 | us-gaap |
Interest Expense
InterestExpense
|
121000 | USD |
us-gaap |
Interest Expense
InterestExpense
|
1033000 | USD | |
us-gaap |
Interest Expense
InterestExpense
|
1206000 | USD | |
us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
800000 | USD | |
us-gaap |
Accretion Of Discount
AccretionOfDiscount
|
400000 | USD | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2015-09-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Fortress Biotech, Inc. | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001429260 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
dei |
Trading Symbol
TradingSymbol
|
FBIO | ||
CY2015Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
47133715 | shares |
CY2015Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2015Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2015Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47133715 | shares |
CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
46494034 | shares |
CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
46494034 | shares |
CY2015Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47133715 | shares |
us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
12575000 | USD | |
us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
0 | USD | |
us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
1507000 | USD | |
us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
0 | USD | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
CY2014Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
4160000 | USD |
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> Reclassifications</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company reclassified debt issuance costs from other assets to notes payable, long-term, net on the unaudited condensed consolidated balance sheets for all periods presented pursuant to the early adoption of Accounting Standards Update (“ASU”) No. 2015-03 - <i>Simplifying the Presentation of Debt Issuance Costs</i>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
CY2015Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
4095000 | USD |
us-gaap |
Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
|
400000 | USD | |
CY2014Q4 | us-gaap |
Trading Securities Cost
TradingSecuritiesCost
|
20002000 | USD |
CY2014 | us-gaap |
Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
|
0 | USD |
us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
3726000 | USD | |
CY2014Q3 | us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
39000 | USD |
CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | USD |
CY2015Q3 | us-gaap |
Other Liabilities
OtherLiabilities
|
2500000 | EUR |
CY2015Q3 | us-gaap |
Other Liabilities
OtherLiabilities
|
2800000 | USD |
CY2014 | fbio |
Payment Of Fund
PaymentOfFund
|
0 | USD |
CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
50000 | USD |
CY2015Q3 | us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
0 | USD |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
1950000 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
250000 | shares | |
CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1700000 | shares |
CY2015Q3 | fbio |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
|
0 | USD |
CY2015Q3 | fbio |
Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue
|
1417000 | USD |
CY2015Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10154952 | shares |
CY2014Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9164131 | shares |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9757654 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8889050 | shares | |
CY2015Q3 | fbio |
Milestone Payments
MilestonePayments
|
500000 | USD |
CY2014Q4 | fbio |
Milestone Payments
MilestonePayments
|
0 | USD |
us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
1600000 | USD | |
CY2015Q3 | us-gaap |
Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
|
0.3169 | pure |
CY2014Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
200000 | USD |
us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
0 | USD | |
us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
19938000 | USD | |
CY2015Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
100000 | USD |
CY2015Q3 | fbio |
Accrued Clinical Study Report
AccruedClinicalStudyReport
|
2823000 | USD |
CY2014Q4 | fbio |
Accrued Clinical Study Report
AccruedClinicalStudyReport
|
0 | USD |
CY2015Q3 | us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
66000 | USD |
us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
153700 | USD | |
CY2014Q3 | us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
40000 | USD |
us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
79000 | USD | |
CY2015Q1 | fbio |
Agreement Description Terms
AgreementDescriptionTerms
|
issue annually to the Company, on the anniversary date of the Founders Agreement, shares of Checkpoint common stock equal to 2.25% of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of Checkpoint common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoints voting equity, equal to 2.25% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of its annual net sales, payable on an annual basis, within 90 days of the end of each calendar year. In the event of a change in control (as defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five times (5x) the product of (i) monthly net sales for the 12 months immediately preceding the change in control and (ii) 4.5% |